Role of gut microbiome on immunotherapy efficacy in melanoma

References

• Kamada N, Nunez G. Role of the gut microbiota in the development and function of lymphoid cells. J Immunol. 2013;190:1389–6. doi:https://doi.org/10.4049/jimmunol.1203100.
   PubMed Web of Science ®Google Scholar
• Viggiano D, Ianiro G, Vanella G, Bibbò S, Bruno G, Simeone G, Mele G. Gut barrier in health and disease: focus on childhood. Eur Rev Med Pharmacol Sci. 2015;19:1077–85. PMID: 25855935.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–41. doi:https://doi.org/10.1016/j.cell.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107:12204–09. doi:https://doi.org/10.1073/pnas.0909122107.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:10. doi:https://doi.org/10.1126/scitranslmed.aat7807.
   Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68. doi:https://doi.org/10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Cancer immunotherapy, part 2: efficacy, safety, and other clinical considerations. Pharm Ther. 2017;42:452–63. PMID: 28674473.
   Google Scholar
• De Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 2005;65:7950–58. doi:https://doi.org/10.1158/0008-5472.CAN-05-0564.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753–58. doi:https://doi.org/10.1158/1078-0432.CCR-18-4070.
   PubMed Web of Science ®Google Scholar
• Ingles Garces AH, Au L, Mason R, Thomas J, Larkin J. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opin Investig Drugs. 2019;28:695–708. doi:https://doi.org/10.1080/13543784.2019.1649657.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(Suppl 4):2–9. doi:https://doi.org/10.1634/theoncologist.13-S4-2.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison, JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116:1935–45. doi:https://doi.org/10.1172/JCI27745.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–76. doi:https://doi.org/10.1126/science.1240537.
   PubMed Web of Science ®Google Scholar
• Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. doi:https://doi.org/10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79. doi:https://doi.org/10.1093/annonc/mdx108.
   PubMed Web of Science ®Google Scholar
• Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020;11:2168. doi:https://doi.org/10.1038/s41467-020-16079-x.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084–89. doi:https://doi.org/10.1126/science.aac4255.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19:848–55. doi:https://doi.org/10.1016/j.neo.2017.08.004.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–08. doi:https://doi.org/10.1126/science.aao3290.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. doi:https://doi.org/10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–70. doi:https://doi.org/10.1126/science.aar6918.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17:271–85. doi:https://doi.org/10.1038/nrc.2017.13.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019;20:e77–e91. doi:https://doi.org/10.1016/S1470-2045(18)30952-5.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Bibbo S, Gasbarrini A. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014;9(4):365–73. doi:https://doi.org/10.1007/s11739-014-1069-4.
   PubMed Web of Science ®Google Scholar
• Zhou CB, Zhou YL, Fang JY. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer. 2021. doi:https://doi.org/10.1016/j.trecan.2021.01.010.
   Google Scholar
• Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–44. doi:https://doi.org/10.1093/annonc/mdy103.
   PubMed Web of Science ®Google Scholar
• Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7:e1507670. doi:https://doi.org/10.1080/2162402X.2018.1507670.
   PubMed Web of Science ®Google Scholar
• Papanicolas LE, Gordon DL, Wesselingh SL, Rogers GB. Not just antibiotics: is cancer chemotherapy driving antimicrobial resistance? Trends Microbiol. 2018;26:393–400. doi:https://doi.org/10.1016/j.tim.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Butel MJ. Probiotics, gut microbiota and health. Med Mal Infect. 2014;44:1–8. doi:https://doi.org/10.1016/j.medmal.2013.10.002.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14. doi:https://doi.org/10.1038/nrgastro.2014.66.
   PubMed Web of Science ®Google Scholar
• Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G, Libra M, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers (Basel). 2019;11(1):38. doi:https://doi.org/10.3390/cancers11010038.
   PubMed Web of Science ®Google Scholar
• Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L, Wettergren Y. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol. 2017;4:e000145. doi:https://doi.org/10.1136/bmjgast-2017-000145.
   PubMed Web of Science ®Google Scholar
• Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491–502. doi:https://doi.org/10.1038/nrgastro.2017.75.
   PubMed Web of Science ®Google Scholar
• Li Y, Elmen L, Segota I, Xian Y, Tinoco R, Feng Y, Fujita Y, Segura Muñoz RR, Schmaltz R, Bradley LM, et al. Prebiotic-induced anti-tumor immunity attenuates tumor growth. Cell Rep. 2020;30:1753–1766 e6. doi:https://doi.org/10.1016/j.celrep.2020.01.035.
   PubMed Web of Science ®Google Scholar
• Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol. 2015;52:7577–87. doi:https://doi.org/10.1007/s13197-015-1921-1.
   PubMed Web of Science ®Google Scholar
• Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017:9. doi:https://doi.org/10.3390/nu9091021.
   Web of Science ®Google Scholar
• Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, Klinder A, O’Riordan M, O’Sullivan GC, Pool-Zobel B, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr. 2007;85:488–96. doi:https://doi.org/10.1093/ajcn/85.2.488.
   PubMed Web of Science ®Google Scholar
• Bindels LB, Neyrinck AM, Claus SP, Le Roy CI, Grangette C, Pot B, Martinez I, Walter J, Cani PD, Delzenne NM, et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 2016;10(6):1456–70. doi:https://doi.org/10.1038/ismej.2015.209.
   PubMed Web of Science ®Google Scholar
• Hernandez-Granados MJ, Franco-Robles E. Postbiotics in human health: possible new functional ingredients? Food Res Int. 2020;137:109660. doi:https://doi.org/10.1016/j.foodres.2020.109660.
   PubMed Web of Science ®Google Scholar
• Rad AH, Aghebati-Maleki L, Kafil HS, Abbasi A. Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment. Crit Rev Food Sci Nutr. 2020:1–17. doi:https://doi.org/10.1080/10408398.2020.1765310.
   Google Scholar
• Bibbo S, Ianiro G, Gasbarrini A, Cammarota G. Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterol Dietol. 2017;63:420–30. doi:https://doi.org/10.23736/S1121-421X.17.02374-1.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–80. doi:https://doi.org/10.1136/gutjnl-2016-313017.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Kelly CR, Mullish BH, Allegretti JR, Kassam Z, Putignani L, Fischer M, Keller JJ, Costello SP, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut. 2019;68(12):2111–21. doi:https://doi.org/10.1136/gutjnl-2019-319548.
   PubMed Web of Science ®Google Scholar
• Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145(8):2021–31. doi:https://doi.org/10.1002/ijc.32003.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang Z-D, Abu-Sbeih H, Sanchez CA, Chang -C-C, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804–08. doi:https://doi.org/10.1038/s41591-018-0238-9.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Rossi E, Thomas AM, Schinzari G, Masucci L, Quaranta G, Settanni CR, Lopetuso LR, Armanini F, Blanco-Miguez A, et al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nat Commun. 2020;11(1):4333. doi:https://doi.org/10.1038/s41467-020-18127-y.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97. doi:https://doi.org/10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar